IMPACT [gngm]
Structural [spco]
Heart disease [dsyn]
Class III [inpr]
ANTIARRHYTHMICS [phsu]
Prevention [topp]
Atrial Fibrillation [patf]
flutter [patf]
Anti-arrhythmic Agent [phsu]
effects [qlco]
Risks [qlco]
One [qnco]
Several [qnco]
Factor [ftcn]
Risk [qlco]
Presence [topp]
Nature [idcn]
Structural [spco]
Heart disease [dsyn]
Time [tmco]
Antiarrhythmic drug [phsu]
Administration [ocac]
Structural [spco]
Disease [dsyn]
Antiarrhythmic drug [phsu]
Interaction [ftcn]
Best [qlco]
Study [mnob]
Class I [clas]
ANTIARRHYTHMICS [phsu]
This [euka]
Review [inpr]
Information [idcn]
Suggest [idcn]
Structural [spco]
Disease [dsyn]
Enhance [acty]
Risk [qlco]
Class III [inpr]
Drugs [phsu]
Well [qlco]
Evidence [ftcn]
Amiodarone [orch, phsu]
Disorders [dsyn]
Potential, Action [celf]
Duration [tmco]
Ventricular hypertrophy [dsyn]
Chronic dilatation [patf]
Dispersion [spco]
Refractory [ftcn]
Including [ftcn]
condition [dsyn]
Cellular [cell]
Reduced [qlco]
Ventricular Fibrillation [dsyn]
Threshold [qlco]
Issue [fndg]
considered [idcn]
choosing [acty]
Antiarrhythmic drug [phsu]
Atrial [bpoc]
Ventricular arrhythmias [patf]
Select [acty]
Monitoring [hlca]
Protocol [inpr]
